To identify if there are any clinical or immunological markers that can help us predict disease relapse in a patient. This knowledge can help the physicians to decide when to administer the maintenance treatment to prevent clinical relapse.
Not Applicable
- Conditions
- Health Condition 1: L102- Pemphigus foliaceousHealth Condition 2: L100- Pemphigus vulgaris
- Registration Number
- CTRI/2020/10/028675
- Lead Sponsor
- All India Institute of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Patients with confirmed pemphigus vulgaris or foliaceus treated with RTX- RA protocol.
Exclusion Criteria
1. Patients who have received RTX cycles in the preceding one year.
2. Patients with other concomitant autoimmune diseases.
3. Pregnant and lactating patients.
4. Patients who cannot come for follow up visits for at least 18 months.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method